B+
Bull case
20%
Probability
Target price
$2.25
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
ENLV
EnlivexANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
RMAT status, an active 182-patient Phase 2b program, and the possibility of a large premium-priced placement create substantial event-driven upside if clinical execution and funding are validated.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Allocetra remains clinical-stage; the Phase 2b trial may encounter enrollment delays, safety issues, weak efficacy, or regulatory disagreement.
Momentum
87
Value
44
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.95 · Bull $2.25 · Bear $0.35Analysis 2026-09-12; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $80.00
Why
Momentum87 · Δ7d -
Value44 · Δ7d -0.0
Sentiment100 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Allocetra remains clinical-stage; the Phase 2b trial may encounter enrollment delays, safety issues, weak efficacy, or regulatory disagreement.
- • Low coverage, loose peers, and the absence of verified analyst revisions materially limit valuation confidence.
- • The shares have fallen sharply despite RMAT designation, while the proposed placement remains conditional and largely treasury-oriented.
Catalyst clock
2026-12-11
Conditional $400 million Rain Foundation private placement
Lead driver: Sentiment · See AI snapshot
Momentum
87
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
44
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
100
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 87.4 / Value 44.4 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-12. Scenario method
Most likely
B
Base case
40%
Probability
Target price
$0.95
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
40%
Probability
Target price
$0.35
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$26.6M
Beta
1.61
Shares Out
16.83M
P/E (TTM) · Derived
0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.26
Rev YoY
-
EPS YoY
-11884.6%
Gross Margin
-
Op Margin
-
Net Debt
-$5.23M
Current Ratio
193.24
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data